[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350937-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350937-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","trends-in-hypofractionated-radiotherapy-use-among-patients-with-breast-or-prostate-cancer-a-multicenter-study-in-osaka-japan","Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan","","This multicenter study in Osaka Prefecture analyzed trends in hypofractionated radiotherapy uptake for eligible breast and prostate cancer patients using linked hospitalbased cancer registry and Diagnostic Procedure Combination records from 69 institutions (diagnosis years 2019–23). Among women receiving partial mastectomy and radiotherapy, hypofractionated radiotherapy rose from 41% to 81%, with highest adoption in high-volume facilities (95%). Among men treated with external-beam radiotherapy, uptake increased from 25% to 48% but slowed after 2021, reaching 79% in high-volume versus 30% and 17% in medium- and low-volume centers. Findings highlight barriers to implementation, especially for prostate cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/trends-in-hypofractionated-radiotherapy-use-among-patients-with-breast-or-prostate-cancer-a-multicenter-study-in-osaka-japan/350937/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/trends-in-hypofractionated-radiotherapy-use-among-patients-with-breast-or-prostate-cancer-a-multicenter-study-in-osaka-japan/350937.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about hypofractionated radiotherapy in Japan?","Question",{"text":63,"@type":64},"It evaluates how frequently hypofractionated radiotherapy is delivered to eligible patients with breast or prostate cancer and how that proportion changes over time.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was hypofractionated radiotherapy use identified in the study?",{"text":68,"@type":64},"Use was determined through insurance claims.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about adoption in high-, medium-, and low-volume facilities?",{"text":72,"@type":64},"In 2023, adoption was highest at high-volume facilities for both cancers, while medium- and especially low-volume facilities showed lower proportions, particularly for prostate cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350937,1790850698,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Journal of Radiation Research, Vol. 67, No. 1, 2026, pp. 104–113 [https://doi.org/10.1093/jrr/rraf082](https://doi.org/10.1093/jrr/rraf082)  \nAdvance Access Publication: 13 January 2026  \nTrends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter  \nstudy in Osaka, Japan  \nToshiki Ikawa 1, 2, * , Toshitaka Morishima 1 , Kayo Nakata 1 ,  \nYoshihiro Kuwabara 1 , Kenji Kishimoto 1 , Naoyuki Kanayama2 , Masahiro Morimoto2, Koji Konishi2 and Isao Miyashiro 1   \n1 Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan  \n2Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan  \n*Corresponding author. Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan. Tel: +81-6-6945-1181; Fax: +81-6-6945-1929; Email: [t_ikawa@radonc.med.osaka-u.ac.jp](t_ikawa@radonc.med.osaka-u.ac.jp)  \n(Received 11 August 2025; revised 17 October 2025; accepted 12 November 2025)  \nABSTRACT  \nThe uptake of hypofractionated radiotherapy in Japan is not well documented. This study examined trends in the proportion of patients with breast or prostate cancer who received hypofractionated radiotherapy, using hospitalbased cancer registry data linked to Diagnostic Procedure Combination records from 69 institutions in Osaka Prefecture (diagnosis years: 2019–23). Eligible patients included 6475 women with unilateral breast cancer (pTisN0M0, pT1–2N0M0 or cT1–2N0M0 before neoadjuvant therapy) who underwent partial mastectomy and radiotherapy at the same hospital and 3274 men with cT1–3N0M0 prostate cancer treated with external-beam radiotherapy without surgery or brachytherapy. The use of hypofractionated radiotherapy was determined through insurance claims. Among the patients with breast cancer, the proportion of those who received hypofractionated radiotherapy increased from 41% in 2019 to 81% in 2023. In 2023, this proportion was highest at facilities with high radiotherapy volume (95%), followed by those with medium (84%) and low (67%) volumes. Among the patients with prostate cancer, the proportion of those who received hypofractionated radiotherapy (hypofractionated intensity-modulated radiotherapy or stereotactic body radiotherapy) increased from 25% in 2019 to 48% in 2023, although the increase slowed after 2021. In 2023, hypofractionated radiotherapy use reached 79% at high-volume facilities, while proportions were lower at medium- (30%) and low-volume (17%) facilities. Hypofractionated radiotherapy use has increased in patients with breast and prostate cancers. However, its adoption in prostate cancer treatment remains limited, particularly in medium-and low-volume facilities. These findings suggest that certain barriers limit its implementation and highlight the need to address them.  \nKeywords: breast neoplasms; hypofractionation; patterns; prostate neoplasms; trends  \nINTRODUCTION  \nRadiotherapy is one of the principal modalities used in cancer treatment and is typically delivered in fractionated doses on consecutive weekdays. For example, postoperative radiotherapy after breastconserving surgery is conventionally delivered at a total dose of 45– 50.4 Gy in 25–28 fractions over ∼5 weeks [ 1]. These prolonged treatment courses place a substantial burden on patients and treatment facilities. In the treatment of breast cancer following breast-conserving surgery and of localized prostate cancer, clinical trials have shown that hypofractionated regimens, which involve fewer fractions and higher  \ndoses per fraction, achieve outcomes comparable to conventionally fractionated radiotherapy [2–4]. Evidence-based guidelines support the use of hypofractionation [ 1, 5, 6], and its adoption is increasing [7–9]. Furthermore, the coronavirus disease 2019 (COVID-19) pandemic, which strained healthcare systems worldwide, may have further promoted its adoption [ 10, 1","cbCaieWoTadUUe26","https://ap.wps.com/l/cbCaieWoTadUUe26","pdf",1393299,"English","# Abstract\n## Study design and data sources\n## Uptake trends in breast cancer\n## Uptake trends in prostate cancer\n## Interpretation and implications\n# Introduction\n## Role of radiotherapy and burden of fractionated schedules\n## Evidence supporting hypofractionation and growing adoption\n## Factors influencing adoption across reimbursement systems\n## Japan’s reimbursement structure and remaining evidence gaps","[{\"question\":\"What question does the study address about hypofractionated radiotherapy in Japan?\",\"answer\":\"It evaluates how frequently hypofractionated radiotherapy is delivered to eligible patients with breast or prostate cancer and how that proportion changes over time.\"},{\"question\":\"How was hypofractionated radiotherapy use identified in the study?\",\"answer\":\"Use was determined through insurance claims.\"},{\"question\":\"What did the study find about adoption in high-, medium-, and low-volume facilities?\",\"answer\":\"In 2023, adoption was highest at high-volume facilities for both cancers, while medium- and especially low-volume facilities showed lower proportions, particularly for prostate cancer.\"}]","Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan | PDF",1790091864,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d7e8141fe2ee0d84bb8a0b97e516f11.webp",983,1269,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30f62b83eb66401940da4a7344f9bccc.webp",982,1268,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae7791c028330b6a22fe6bc5c3d49be5.webp",981,1266,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/809683b6353c7f3659cff6027c950025.webp",980,1265]